

HuaMedicine
华领医药

1 2

3 4 5

6 7 8

a

b

ث


H M
H
IA

3

72

72

20,000


20,000 2

14

β

2


Copyright © Hua Medicine 2024




2023 12 .
2023 251,000 76.6 2022
335.2%

Copyright © Hua Medicine 2024









52

10.78 /

46%

Copyright © Hua Medicine 2024







GLP-1

TIR

Source: Chen L, Zhang JY et al. Nature Communications , A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity 2023, 3 1405.

Copyright © Hua Medicine 2024


Hyper
Hyper
Hypo
Hypo
Insulin
SU Glinide
Glucagon
SGLT2
Metformin
PPAR,TZD




Copyright © Hua Medicine 2024

Ferrannini T2D OGTT


GLP-1 GLP-1 OGTT 30 T2D


GLP-1




Goto-Kakizaki

26 GK




P=0.0002
***
1.8
1.2
0.0
GK

HFD /



19


19 10 18 38


45

Copyright © Hua Medicine 2024

24

TIR





TIR 46 83.7%




TIR

Diabetes Obes Metab.2023 Jun 29. doi: 10.1111/dom.15179

Copyright © Hua Medicine 2024



H M
H
IA



GK

2


GK





Copyright © Hua Medicine 2024

HMS0266 Fmr1 X




H M

-
-
-
-

R

( )

Copyright © Hua Medicine 2024

R

( )

Copyright © Hua Medicine 2024

( )

R

( )

R **R**

+ 889.4
+ 8.1
+ 69.1
+ 3.7


R

( )

65.1
49.0
16.5

Copyright © Hua Medicine 2024





) .(.3